The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV)
- PMID: 27861337
- PMCID: PMC5120894
- DOI: 10.1097/MD.0000000000005066
The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV)
Abstract
Mental and emotional health (MEH) impairment is commonly encountered in hepatitis C patients. Although the exact mechanism remains unknown, alterations in neurotransmitter and cytokine levels maybe associated with hepatitis C virus (HCV)-related MEH issues.The aim of the study was to assess association of serum biomarkers with self-reports of MEH in HCV patients before treatment and after achieving sustained virologic response (SVR).The HCV genotype-1-infected patients who achieved SVR at 12 weeks after treatment with ledipasvir (LDV)/sofosbuvir (SOF) ± ribavirin (RBV) were selected. Frozen serum samples from baseline, end of treatment (EOT), and posttreatment week 4 (PTW4) were used to assay 16 cytokines and monoamine neurotransmitters. Validated self-reports were used to assess MEH.Hundred patients were evaluated. Mean age was 53 years (57% male, 86% white). Compared with baseline, emotional well-being and emotional health significantly increased by EOT, and role emotional, emotional well-being, and emotional health significantly increased at PTW4 in the RBV-containing arm (P < 0.05). In patients taking LDV/SOF + RBV, serotonin levels were significantly decreased at PTW4 compared with baseline (P = 0.046). Compared with baseline, there were significant decreases in interleukin (IL)-10 levels at EOT and PTW4 in both treatment groups. The changes in IL-8 also differed significantly between LDV/SOF + RBV and LDV/SOF groups (P < 0.05). Changes in dopamine and tryptophan levels at EOT correlated with increasing emotional health scores, whereas changes in monocyte chemoattractant protein-1 at EOT and IL-8 at PTW4 correlated with increasing mental health scores. The neurotransmitters and cytokines were found to be independent predictors of MEH scores in multiple regression analysis.Cytokine and neurotransmitter changes are associated with mental and emotional health. Patient-reported outcome scores change during and after treatment.
Conflict of interest statement
ZMY has received research grants or is a consultant to Abbvie, BMS, Gilead, GSK, and Intercept. There are no other conflicts of interest related to this manuscript for other authors.
Similar articles
-
Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis.Int J Infect Dis. 2017 Feb;55:56-71. doi: 10.1016/j.ijid.2016.12.023. Epub 2016 Dec 29. Int J Infect Dis. 2017. PMID: 28040553
-
Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels.J Viral Hepat. 2015 Dec;22(12):977-82. doi: 10.1111/jvh.12448. Epub 2015 Aug 17. J Viral Hepat. 2015. PMID: 26280786 Clinical Trial.
-
Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.Transpl Infect Dis. 2017 Feb;19(1). doi: 10.1111/tid.12647. Epub 2017 Jan 11. Transpl Infect Dis. 2017. PMID: 27943544
-
The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir, Ledipasvir, and Ribavirin in Patients with Chronic Hepatitis C, Genotype 1, Who Have Cirrhosis and Have Failed Prior Therapy: A Systematic Review and Meta-Analysis.Can J Gastroenterol Hepatol. 2017;2017:6468309. doi: 10.1155/2017/6468309. Epub 2017 Mar 6. Can J Gastroenterol Hepatol. 2017. PMID: 28367429 Free PMC article.
-
Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis.Virol J. 2021 Jul 27;18(1):156. doi: 10.1186/s12985-021-01625-w. Virol J. 2021. PMID: 34315488 Free PMC article.
Cited by
-
Importance of fatigue and its measurement in chronic liver disease.World J Gastroenterol. 2019 Jul 28;25(28):3669-3683. doi: 10.3748/wjg.v25.i28.3669. World J Gastroenterol. 2019. PMID: 31391765 Free PMC article. Review.
-
Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C.PLoS One. 2018 Dec 19;13(12):e0208112. doi: 10.1371/journal.pone.0208112. eCollection 2018. PLoS One. 2018. PMID: 30566421 Free PMC article.
-
Successful Antiviral Therapy Reduces Risk of Schizophrenia Among Chronic Hepatitis C Patients: A Nationwide Real-World Taiwanese Cohort (T-COACH).Open Forum Infect Dis. 2020 Aug 31;7(10):ofaa397. doi: 10.1093/ofid/ofaa397. eCollection 2020 Oct. Open Forum Infect Dis. 2020. PMID: 33376753 Free PMC article.
References
-
- Quelhas R, Lopes A. Psychiatric problems in patients infected with hepatitis C before and during antiviral treatment with interferon-alpha: a review. J Psychiatr Pract 2009; 15:262–281. - PubMed
-
- Fazel Y, Lam B, Golabi P, et al. Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C. Expert Opin Drug Saf 2015; 14:1317–1326. - PubMed
-
- Manne V, Sassi K, Allen R, et al. Hepatitis C and work impairment: a review of current literature. J Clin Gastroenterol 2014; 48:595–599. - PubMed
-
- Cacoub P, Gragnani L, Comarmond C, et al. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis 2014; 46 (suppl 5):S165–S173. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials